LENSAR earnings release, August 13, 2026

LENSAR, Inc. (LNSR) · Form 8-K, Item 2.02 · Filed · SEC filing

LENSAR®

Reports Second Quarter 2026 Results and Provides Business Update

10 ALLY Robotic Cataract Laser Systems®

(“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026

Second Quarter Recurring Revenue was $13.7 million

Total Laser Installed Base Climbs to 445 Systems, Driven by 30% Growth in ALLY Placements

ORLANDO, Fla. (Aug 13, 2026)

- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2026 and provided an update on key operational initiatives.

“In all metrics we delivered a significant second quarter, highlighted by 18% total revenue growth and 20% recurring revenue growth over the second quarter of 2025, and our strongest Adjusted EBITDA performance to date along with positive Net Income. These results reflect the continued strength of our business model, increasing utilization across our installed base, and sustained demand for the ALLY System,” said Nick Curtis, President and CEO of LENSAR. “Importantly, procedure revenue grew 23% over the second quarter last year as surgeons continued to increase the number of procedures performed using ALLY, reinforcing our belief in the solid health of our underlying business in realizing the long-term potential of our recurring revenue model. The growth we achieved during the second quarter gives us continued confidence in the trajectory of the business. Our increasing installed base, expanding recurring revenue and healthy backlog of pending installations exiting the second quarter position us well as we continue executing on our commercial strategy, LENSAR maintains a sharp focus on driving long-term value for our shareholders, as well as our surgeon partners and the patients they serve.”

LENSAR Q2 2026 Financial Summary

*N/M = Not meaningful due to change from a loss to positive earnings.

Second Quarter 2026 Financial Results

In addition to the revenue growth summarized above, during the three months ended June 30, 2026, the Company placed 10 ALLY Systems, bringing the total installed ALLY base to approximately 215 at quarter end. As of June 30, 2026, the Company had a backlog of 13 ALLY Systems pending installation.

The following table provides information about revenue and recurring revenue, which we consider to be all components of our revenue except for the sales of our systems:

The following table provides information about procedure volume:

Net income and Adjusted EBITDA increased due to improved revenue, lower operating expenses, and a $1.1 million tariff refund. Net income growth was offset by lower non-cash income related to the change in fair value of warrant liabilities.

Cash, cash equivalents, and investments totaled $13.6 million as of June 30, 2026, compared to $18.0 million at December 31, 2025.

Conference Call

LENSAR management will host a conference call and live webcast to discuss the results and provide an update on the Company’s go-forward strategy today, August 13, 2026, at 8:30 a.m. ET.

To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call. The live webcast can be accessed under “Events & Presentations” in the Investor Relations section of the company’s website at https://ir.lensar.com. The call and webcast replay will be available for 30 days.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System® as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.

Financial statements

Income Statement

LENSAR Q2 2026 Financial Summary

Q2 2026Q2 2025% Change
Revenue$16.5M$13.9M18.0%
Recurring revenue$13.7M$11.4M20.0%
Procedure revenue$10.2M$8.3M23.0%
Procedure volume58,68252,10013.0%
Recurring revenue %83.0%82.0%1.0%
Total Laser Installed Base4454109.0%
Total ALLY Installed Base21516530.0%
Net Income (Loss)$3.5M$(1.8)MN/M
Adjusted EBITDA$3.6M$(0.3)MN/M

Income Statement

Three Months Ended June 30, (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
System2,8092,5763,6455,208
Recurring revenue:Procedure10,2338,33419,47316,620
Recurring revenue:Lease1,7721,6453,4533,529
Recurring revenue:Service1,6811,3803,3522,737
Recurring revenue:Total recurring revenue13,68611,35926,27822,886
Recurring revenue:Total revenue16,49513,93529,92328,094
Recurring revenue:Recurring revenue %83.0%8288.0%81

Income Statement

Three Months Ended June 30, — (In thousands, except per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
RevenueProduct13,04210,91023,11821,828
RevenueLease1,7721,6453,4533,529
RevenueService1,6811,3803,3522,737
RevenueTotal revenue16,49513,93529,92328,094
Cost of revenue (exclusive of amortization)Product3,8394,3157,7868,781
Cost of revenue (exclusive of amortization)Lease8518591,7401,689
Cost of revenue (exclusive of amortization)Service2,0291,7374,2393,475
Cost of revenue (exclusive of amortization)Total cost of revenue6,7196,91113,76513,945
Operating expensesSelling, general and administrative expenses6,14111,6588,67022,807
Operating expensesResearch and development expenses1,2731,4252,6582,959
Operating expensesAmortization of intangible assets228230457462
Operating expensesTotal operating expenses7,64213,31311,78526,228
Operating expensesOperating income (loss)2,134-6,2894,373-12,079
Other income (expense)Change in fair value of warrant liabilities1,2304,33225,178-17,382
Other income (expense)Acquisition-related income10,000
Other income (expense)Other income, net171193316352
Other income (expense)Net income (loss)3,535-1,76439,867-29,109
Other comprehensive income (loss)Change in unrealized loss on investments-6-4-9
Other comprehensive income (loss)Net income (loss) and comprehensive income (loss)3,535-1,77039,863-29,118
Income (loss) per common share:Basic0.14-0.151.62-2.46
Income (loss) per common share:Diluted0.1-0.150.61-2.46
Weighted-average number of common shares used in calculation of net income (loss) per common share:Basic12,29711,93712,23011,856
Weighted-average number of common shares used in calculation of net income (loss) per common share:Diluted23,02711,93724,02411,856

Balance Sheet

June 30, 2026 — BALANCE SHEETS (In thousands, except per share amounts)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents13,56512,974
Current assets:Short-term investments5,004
Current assets:Accounts receivable, net of allowance of $79 and $62, respectively6,1706,377
Current assets:Notes receivable, net of allowance of $10 and $6, respectively501295
Current assets:Inventories24,87121,520
Current assets:Prepaid and other current assets1,919601
Current assets:Total current assets47,02646,771
Current assets:Property and equipment, net445505
Current assets:Equipment under lease, net14,41415,485
Current assets:Notes and other receivables, long-term, net of allowance of $12 and $15, respectively582731
Current assets:Intangible assets, net4,7345,191
Current assets:Other assets2,3572,747
Current assets:Total assets69,55871,430
Current liabilities:Accounts payable11,19318,982
Current liabilities:Accrued liabilities4,7287,771
Current liabilities:Deferred revenue2,9273,074
Current liabilities:Operating lease liabilities792747
Current liabilities:Acquisition-related deposit10,000
Current liabilities:Total current liabilities19,64040,574
Current liabilities:Long-term accounts payable3,750
Current liabilities:Long-term operating lease liabilities1,5891,988
Current liabilities:Warrant liabilities15,01640,194
Current liabilities:Other long-term liabilities874909
Current liabilities:Total liabilities40,86983,665
Current liabilities:Series A Redeemable Convertible Preferred Stock, par value $0.01 per share, 20 shares authorized at June 30, 2026 and December 31, 2025; 20 shares issued and outstanding at June 30, 2026 and December 31, 2025; aggregate liquidation preference of $20,000 at June 30, 2026 and December 31, 202513,78413,784
Stockholders’ equity (deficit):Common stock, par value $0.01 per share, 150,000 shares authorized at June 30, 2026 and December 31, 2025; 12,282 and 11,993 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively123120
Stockholders’ equity (deficit):Additional paid-in capital152,490151,432
Stockholders’ equity (deficit):Accumulated other comprehensive income4
Stockholders’ equity (deficit):Accumulated deficit-137,708-177,575
Stockholders’ equity (deficit):Total stockholders’ equity (deficit)14,905-26,019
Full release

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding trends in worldwide procedure volume, ALLY’s commercialization and the Company’s operational and financial performance and long-term strategic goals. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.... (truncated)losses and ability to achieve or sustain profitability; our ability to develop, receive and maintain regulatory clearance or certification of and successfully commercialize the ALLY System and to maintain our LENSAR Laser System; the impact to our business, financial condition, results of operations and our suppliers and distributors as a result of global macroeconomic conditions; the willingness of patients to pay the price difference for our products compared to a standard cataract procedure covered by Medicare or other insurance; our ability to grow our U.S. sales and marketing organization or maintain or grow an effective network of international distributors; our future capital needs and our ability to raise additional funds on acceptable terms, or at all; the impact to our business, financial condition and results of operations as a result of a material disruption to the supply or manufacture of our systems or necessary component parts for such system or material inflationary pressures or enacted tariffs affecting pricing of component parts; our ability to compete against competitors that have longer operating histories, more established products and greater resources than we do; our ability to address the numerous risks associated with marketing, selling and leasing our products in markets outside the United States; the impact to our business, financial condition and results of operations as a result of exposure to the credit risk of our customers; our ability to accurately forecast customer demand and manage our inventory levels; the impact to our business, financial condition and results of operations if we are unable to secure adequate coverage or reimbursement by government or other third-party payors for procedures using our ALLY System or our other products, or changes in such coverage or reimbursement; the impact to our business, financial condition and results of operations of product liability suits brought against us; risks related to government regulation applicable to our products and operations; and risks related to our intellectual property and other intellectual property matters. In addition, a number of other important factors could cause the Company’s actual future results and other future circumstances to differ materially from those expressed in any forward-looking statements, including but not limited to the other important factors that are disclosed under the heading “Risk Factors” contained in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, to be filed with the SEC, each accessible on the SEC’s website at www.sec.gov and the Investor Relations section of the Company’s website at https://ir.lensar.com.

All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether because of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Non-GAAP Financial Measures:

The Company prepares and analyzes operating and financial data and non-GAAP measures to assess the performance of its business, make strategic and offering decisions and build its financial projections. The key non-GAAP measures it uses are EBITDA and Adjusted EBITDA. EBITDA is defined as net loss before interest expense, interest income, income tax expense, depreciation and amortization expenses. EBITDA is a non-GAAP financial measure. EBITDA is included in this filing because we believe that EBITDA provides meaningful supplemental information for investors regarding the performance of our business and facilitates a meaningful evaluation of actual results on a comparable basis with historical results. Adjusted EBITDA is also a non-GAAP financial measure. We believe Adjusted EBITDA, which is defined as EBITDA and further excluding stock-based compensation expense, change in fair value of warrant liabilities, and acquisition-related income and costs provides meaningful supplemental information for investors when evaluating our results and comparing us to peer companies as stock-based compensation expense and change in fair value of warrant liabilities are significant non-cash charges, and acquisition-related income and costs are not recurring. We use these non-GAAP financial measures in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance and, therefore, any non-GAAP measures we use may not be directly comparable to similarly titled measures of other companies. Investors should not consider our non-GAAP financial measures in isolation or as a substitute for an analysis of our results as reported under GAAP.

Reconciliations of EBITDA and Adjusted EBITDA to their most comparable GAAP financial measure are set forth below.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · LENSAR earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.